Status:

NOT_YET_RECRUITING

Pulsed-Field-Ablation to Treat Atrial fiBRillation With a novEl multimodalIty Generator

Lead Sponsor:

University Hospital Freiburg

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

In this first-in-human clinical trial a novel generator (INTELLAPULSE), designed and built by Stockert, which supports highly flexible PFA protocols as well as RF interventions will be used. For 12 mo...

Detailed Description

The principal safety and efficacy of PFA have been established in previous studies, showing low compli¬cation rates, short procedure times, and non-inferior/ superior efficiency compared to thermal ab...

Eligibility Criteria

Inclusion

  • new onset atrial fibrillation

Exclusion

  • age \<18 years
  • previous left atrial ablation
  • lack or withdrawal of written informed consent
  • unable to receive ablation therapy

Key Trial Info

Start Date :

July 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06156644

Start Date

July 1 2025

End Date

December 1 2026

Last Update

January 3 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Pulsed-Field-Ablation to Treat Atrial fiBRillation With a novEl multimodalIty Generator | DecenTrialz